Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mechanisms for industry input on FDA guidance agenda suggested in comments.

This article was originally published in The Gray Sheet

Executive Summary

GUIDANCE DOCUMENT "CALENDAR" COULD PROVIDE OPPORTUNITY FOR INDUSTRY PROPOSALS for FDA guidance documents, in addition to listing the agency's guidance development plans, Steris says in recent comments on FDA's good guidance practices proposal ("The Gray Sheet" March 11, I&W-3). The calendar "would list all planned guidance document activities, including all opportunities for written and oral comments, and would allow members of the public to propose guidance document topics," the sterilizer company suggests. FDA or an industry committee "may need to loosely filter" the proposals "to avoid an explosion of meritless calendar listings," Steris adds.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel